5-AMINO-1MQ

5-Amino-1MQ is a research compound investigated for its role in modulating cellular metabolism through inhibition of Nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme involved in nicotinamide metabolism, methylation balance, and energy regulation within cells. Elevated NNMT activity has been associated with metabolic dysfunction, obesity, aging-related processes, and certain cancers, making it an active target of biomedical research.

Mechanism of Action

5-Amino-1MQ functions as a selective NNMT inhibitor. By reducing NNMT activity, researchers believe the compound may help preserve intracellular nicotinamide levels and influence pathways connected to NAD+ biosynthesis and methyl donor utilization. These mechanisms are being studied for their potential impact on mitochondrial activity, cellular energy expenditure, and metabolic flexibility.

Areas of Scientific Interest

Current preclinical research involving 5-Amino-1MQ includes:

• Cellular energy metabolism and mitochondrial efficiency
• NAD+ salvage pathway regulation
• Adipocyte biology and fat metabolism
• Insulin sensitivity and glucose utilization
• Epigenetic regulation and methylation balance
• Healthy aging and metabolic resilience
• Oncology research involving NNMT-overexpressing tumors

Research Findings

Animal and in vitro studies have reported that NNMT inhibition may influence body composition, energy expenditure, and metabolic signaling pathways. Investigators are also examining how modulation of NNMT affects inflammation, oxidative stress, and cellular adaptation to metabolic demand.

Scientific Background

NNMT catalyzes the methylation of nicotinamide using S-adenosyl-L-methionine (SAM) as a methyl donor, producing 1-methylnicotinamide (1-MNA). Because this reaction intersects with both methylation pathways and NAD+ metabolism, NNMT has become a target of growing interest in metabolic and longevity-related research.

Research Use Disclaimer

5-Amino-1MQ is intended for laboratory and research purposes only. It is not approved by the U.S. Food and Drug Administration for the diagnosis, treatment, cure, or prevention of any disease. Human clinical data remain limited, and additional studies are required to evaluate safety, pharmacokinetics, and long-term biological effects.